Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient
- 22 February 2021
- journal article
- letter
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 62 (8), 2026-2029
- https://doi.org/10.1080/10428194.2021.1889537
Abstract
Post-transplant lymphoproliferative disorders (PTLDs) occur with an incidence of 0.9–2.6% after liver transplantation [1]. PTLD is associated with high mortality: the overall survival at 1-year aft...Keywords
This publication has 13 references indexed in Scilit:
- Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic reviewJournal of the American Academy of Dermatology, 2019
- Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patientsActa Neuropathologica Communications, 2019
- PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphomaBlood, 2017
- Mutational landscape of B‐cell post‐transplant lymphoproliferative disordersBritish Journal of Haematology, 2017
- Targetable genetic features of primary testicular and primary central nervous system lymphomasBlood, 2016
- On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activationScience Translational Medicine, 2015
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic reviewLiver International, 2010
- Post-Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and SurvivalAmerican Journal of Transplantation, 2006